SCHEMBL3557784

SCHEMBL3557784

Cc1ccc(C(c2nnnn2-c2c(C)cccc2C)N2CCN(CC=Cc3ccccc3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.54
NPSR1 Q6W5P4 6/20 0.54
ALDH1A1 P00352 6/20 0.54
SLC6A2 P23975 5/20 0.54
SLC6A3 Q01959 5/20 0.54
HIF1A Q16665 4/20 0.54
SLC6A4 P31645 4/20 0.54
CYP3A4 P08684 3/20 0.54
CYP2D6 P10635 3/20 0.54
OPRM1 P35372 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
CHRM2 P08172 2/20 0.54
CHRM4 P08173 2/20 0.54
HTR1A P08908 2/20 0.54
CHRM5 P08912 2/20 0.54
ADRA2A P08913 2/20 0.54
ADORA3 P0DMS8 2/20 0.54
CHRM1 P11229 2/20 0.54
DRD2 P14416 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13499378 1.00 LMNA (0.54) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL3557782 1.00 LMNA (0.54) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL13499377 1.00 LMNA (0.54) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL13499373 0.95 LMNA (0.55) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL3565166 0.95 LMNA (0.55) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL13499370 0.95 LMNA (0.55) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL3565163 0.95 LMNA (0.55) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL3568985 0.95 LMNA (0.60) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL13499283 0.95 LMNA (0.60) LMNANPSR1ALDH1A1SLC6A2SLC6A3
SCHEMBL3568988 0.95 LMNA (0.60) LMNANPSR1ALDH1A1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659276-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2010-02-09 US claimed
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2009-06-04 US claimed
US-7514438-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2009-04-07 US claimed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
US-7514438-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2009-04-07 US disclosed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST MCHR1, MC1R, NPY1R LMNA 2996/4885NPSR1 35/4885ALDH1A1 2113/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R LMNA 2996/4885NPSR1 35/4885ALDH1A1 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.